MAIA Biotechnology
thio trial planned to expand best combination arms | MAIA Biotechnology
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
23 of 39
Similar slides by MAIA Biotechnology
See diffirences between slides (animation)
Investor Presentation
January 2024
thio trial planned | MAIA Biotechnology
Investor Presentation
January 2024
thio trial planned nae thio | MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
Investor Presentation
October 2023
thio trial planned a | MAIA Biotechnology
Related slides by other companies
OKYO Pharma
Results
June 2023
phase trial design rota | OKYO Pharma
Avenue Therapeutics
IPO
October 2022
safety and efficacy has been demonstrated in two phase trials in over patients | Avenue Therapeutics
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase sad mad trial initiated in trial design randomized double blind trial population healthy subjects sad mad primary objectives assess the safety tolerability of sad and mad of evaluate the profile of after single and multiple doses trial update enrollment is progressing in several sad cohorts and at least one cohort has been extremely safe and well tolerated complete safety and data expected study underway | Recursion Pharmaceuticals
Ocuphire Pharma
Investor Presentation
November 2021
safety findings | Ocuphire Pharma
Other recent decks by MAIA Biotechnology
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights